Matthew D. Wright, M.D.
Department of General Oncology, Division of Cancer Medicine
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, The Woodlands, TX
Education & Training
Degree-Granting Education
| 2016 | Georgetown University School of Medicine, Washington, DC, USA, MD, Medicine |
Postgraduate Training
| 2019-2022 | Clinical Fellowship, Hematology-Oncology, Cleveland Clinic Foundation, Cleveland, OH |
| 2016-2019 | Clinical Residency, Internal Medicine, Case Western Reserve University/University Hospitals, Cleveland, OH |
Board Certifications
| 2019 | American Board of Internal Medicine, Certification in Internal Medicine |
Experience & Service
Other Appointments/Responsibilities
Member, Cleveland Clinic Internal Medicine Residency Hematology-Oncology Interest Group, Cleveland, OH, 2021 - 2022
Member, Cleveland Clinic Hematology-Oncology Program Evaluation Committee, Cleveland, OH, 2020 - 2022
Honors & Awards
| 2020 | Cleveland Clinic Caregiver Appreciation Award (3) |
| 2014 | McVay Scholarship |
| 2012 | Summa cum laude, Case Western Reserve University |
| 2012 | Phi Beta Kappa, National Academic Honor Society |
| 2012 | Sigma Delta Pi, National Collegiate Hispanic Studies Honor Society |
| 2011 | Outstanding Junior Arts & Sciences |
| 2011 | Mortar Board, National Collegiate Honor Society |
| 2010 | Phi Beta Kappa Prize |
| 2008 | President's Scholarship |
| 2008 | Bishop Lamb Award |
| 2008 | Leaders of Tomorrow Award |
| 2008 | President's Award (Co-Valedictorian) |
| 2007 | Senior Class President |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Varma R, Wright M, Abraham J, Kruse M. Immune Checkpoint Inhibition in Early-stage Triple-negative Breast Cancer. Expert Rev Anticancer Ther 22(11):1225-38. e-Pub 2022. PMID: 36278877.
- Oesterreich S, Nasrazadani A, Zou J, Carleton N, Onger T, Wright MD, Li Y, Demanelis K, Ramaswamy B, Tseng G, Lee AV, Williams N, Kruse M. Clinicopathological Features and Outcomes Comparing Patients with Invasive Ductal and Lobular Breast Cancer. J Natl Cancer Inst. e-Pub 2022. PMID: 36239760.
- Cocco D, ElSherif A, Wright MD, Dempster MS, Kruse ML, Li H, Valente SA. Invasive Lobular Breast Cancer: Data to Support Surgical Decision Making. Ann Surg Oncol 28(10):5723-5729, 2021. e-Pub 2021. PMID: 34324111.
- Wright MD, Abraham MJ. Preclinical Discovery and Development of Abemaciclib used to Treat Breast Cancer. Expert Opin Drug Discov 16(5):485-496, 2021. e-Pub 2021. PMID: 33280445.
- Wright MD, Poe MD, DeRenzo A, Haldal S, Escolar ML. Developmental Outcomes of Cord Blood Transplantation for Krabbe Disease: A 15-year study. Neurology 89(13):1365-1372, 2017. e-Pub 2017. PMID: 28855403.
Abstracts
- Nelson AA, Wright MD, Khaki AR, Diamantopoulos LK, Kyasaram RK, Nezami B, Dawsey S, Patel K, Eitman C, MacLennan G, Grivas P, Mendiratta P, Ponsky LE, Hoimes CJ. Association of Early Bone Metastases and Outcomes of the Bone Predominant Metastatic Urothelial Carcinoma (BPmUC) Phenotype. J Clin Oncol 37, 2019.
- Nelson AA, Opneja A, Nezami BG, Ponsky LE, Wright, MD, Mergler P, Kyasaram RK, Eitman C, Patel K, MacLennan G, Cooney MM, Grivas P, Barata PC, Garcia JA, Fu P, Hoimes CJ. Patterns of Metastases, Treatment (tx), and Outcomes in Bone Predominant (BP) Metastatic Urothelial Carcinoma (mUC). J Clin Oncol 36, 2018.